These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38362680)

  • 1. Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.
    González MM; Sanz-Pastor AG; Gómez RÁ; Torrecilla NB; Moreno DM; Fernández LG; Rivas AM; Guerra AL; Álvarez R; Arranz JÁ; Rodas IM; Escudero V; Sanjurjo M; Vallejo JM; Martín M; Albarrán OG
    Endocr Metab Immune Disord Drug Targets; 2024; 24(14):1628-1639. PubMed ID: 38362680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors-Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre.
    Elshafie O; Khalil AB; Salman B; Atabani A; Al-Sayegh H
    Endocrinol Diabetes Metab; 2024 Jul; 7(4):e00505. PubMed ID: 38932429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
    Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
    Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 8. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center.
    Barlas T; Sutcuoglu O; Akdogan O; Balos Toruner F; Akturk M; Ozdemir N; Yazici O; Eroglu Altinova A
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39194584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
    Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
    Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
    Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
    Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
    [No Abstract]   [Full Text] [Related]  

  • 11. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
    Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
    Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
    Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy.
    Wang Q; Wu T; Zhao R; Li Y; Chen X; Shen S; Zhang X
    Endocr Pract; 2024 Oct; 30(10):943-950. PubMed ID: 39004306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study.
    Gao R; Li C; Zhang S; Liao N; Guan H
    Endocrine; 2024 Sep; 85(3):1446-1455. PubMed ID: 38951449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors.
    Lima Ferreira J; Costa C; Marques B; Castro S; Victor M; Oliveira J; Santos AP; Sampaio IL; Duarte H; Marques AP; Torres I
    Cancer Immunol Immunother; 2021 Feb; 70(2):299-309. PubMed ID: 32712715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 18. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.
    Kimbara S; Fujiwara Y; Iwama S; Ohashi K; Kuchiba A; Arima H; Yamazaki N; Kitano S; Yamamoto N; Ohe Y
    Cancer Sci; 2018 Nov; 109(11):3583-3590. PubMed ID: 30230649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.
    Brilli L; Danielli R; Campanile M; Secchi C; Ciuoli C; Calabrò L; Pilli T; Cartocci A; Pacini F; Di Giacomo AM; Castagna MG
    J Endocrinol Invest; 2021 Aug; 44(8):1719-1726. PubMed ID: 33367977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.